Tangningtongluo Tablet for People With Prediabetes
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Prediabetes is an intermediate transition to hyperglycemia between normal blood glucose and
diabetes, including impaired fasting glucose (IFG), impaired glucose tolerance (IGT)and the
presence of a combination of the two.
At present, the prediabetes population in China is very large. Timely detection of this
sub-health population and effective intervention are the key to prevent or delay diabetes and
related complications. Basic research showed that Tangningtongluo had a good hypoglycemic
effect on db/db diabetic mice and STZ induced diabetic rats, and could alleviate pancreatic
islet destruction and insulin resistance to some extent.
In this study, the therapeutic effects of Tangningtongluo pian provided by Guizhou bailing
Enterprise Group Pharmaceutical Co., Ltd on patients with prediabetes was evaluated
clinically. A multi-center, randomized, double-blind, placebo-controlled clinical trial was
designed to provide evidence-based medical evidence for Tangningtongluo pian in the treatment
of prediabetes . In the design of this trial, the therapeutic effects and safety of
Tangningtongluo pian in the treatment of prediabetes were evaluated with Tangningtongluo pian
in the treatment group and placebo in the control group.